Related Experiment Video

Updated: Apr 6, 2026

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones
06:06

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

27.1K

Methoxetamine-related deaths in the UK: an overview

Stefania Chiappini1, Hugh Claridge1, John M Corkery1

  • 1National Programme on Substance Abuse Deaths (NPSAD), International Centre for Drug Policy, St George's, University of London, Cranmer Terrace, London, UK.

Human Psychopharmacology
|July 29, 2015
PubMed
Abstract

Insights

Methoxetamine (MXE) was implicated in eight UK fatalities between 2011-2013, often combined with other drugs. Further research into MXE toxicity is crucial for harm reduction strategies.

Area of Science:

  • Forensic Toxicology
  • Clinical Toxicology
  • Public Health

Background:

  • Novel psychoactive substances (NPS) pose emerging public health challenges.
  • Methoxetamine (MXE) is a dissociative anesthetic with increasing recreational use.
  • Understanding the toxicological profile of NPS like MXE is critical for public safety.

Purpose of the Study:

  • To update data on methoxetamine (MXE)-related fatalities from 2011-2013.
  • To present findings at the Second International Conference on Novel Psychoactive Substances.
  • To inform healthcare professionals about MXE risks.

Main Methods:

  • Data extracted from the National Programme on Substance Abuse Deaths database.
  • Inclusion of drug-related deaths reported by UK Coroners and other data suppliers.
  • Analysis of eight cases involving MXE identified by September 3, 2013.

Main Results:

  • Eight MXE-involved fatalities reported between 2011-2013.
  • Median age of decedents was 27 years; predominantly White (6/8) and male (7/8).
  • MXE was detected in all cases, implicated in 6 deaths, and frequently co-ingested with other substances (7/8 cases).

Conclusions:

  • Further research into MXE health effects and toxicity is warranted.
  • Healthcare professionals require awareness of MXE's potential harms.
  • Early intervention measures are needed to minimize MXE-related poisonings and fatalities.
Keywords:
MXENPSdesigner drugslegal highmethoxetaminenovel psychoactive substances

More Related Videos

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry11:14

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry

Published on: October 2, 2016

12.2K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

10.5K

Related Concept Videos

Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
131
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
880
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
973
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
81
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
184